41 results on '"Blackman, Samuel C."'
Search Results
2. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
3. Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
4. Activity of RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion
5. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
6. Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion
7. Data Supplement from Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
8. FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.
9. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors
10. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
11. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib
12. IMG-05. INITIAL RADIOGRAPHIC ASSESSMENT OF DWI AND ADC VALUES IN CHILDREN AND YOUNG ADULTS TREATED WITH DAY101 (TAK-580) FOR RECURRENT LOW-GRADE GLIOMAS (LGG) HARBORING MAPK ALTERATIONS
13. Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors
14. Contributors
15. Cancer and the Nervous System
16. PRAY WITH ME
17. Hematologic Emergencies: Acute Anemia
18. Forehead swelling caused by Pottʼs puffy tumor in a 9-year-old boy with sinusitis
19. Identification and functional characterization of thromboxane A2 receptors in Schwann cells
20. Cancer immunotherapy: Checkpoint inhibitors, adoptive cell therapy, and beyond
21. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib
22. Lesser Harms: The Morality of Risk in Medical Research
23. Assessment of Cellular Localization of the Thromboxane A2 Receptor by Immunocytochemistry
24. Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
25. Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation
26. Abstract 3773: Absolute bioavailability of BRAF inhibitor GSK2118436: Use of a microtracer study in patients with cancer
27. Abstract 1752: A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
28. Abstract 3766: Effects of a high-fat meal on the pharmacokinetics of orally administered GSK2118436 in patients with BRAF mutation-positive tumors
29. Abstract B155: A phase I study of the MEK inhibitor GSK1120212 (GSK212) in combination with PI3K/mTOR inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors.
30. Abstract 26: Notch pathway inhibition with MK-0752 leads to dose- and time-dependent transcriptional alterations in proliferation, PI3K, andWntpathway genes in plucked human hair follicles
31. Abstract B41: Identification of a time‐ and dose‐responsive transcriptional signature of Notch pathway inhibition in plucked human hair follicles following exposure to the gamma‐secretase inhibitor MK‐0752
32. Metachronous Mediastinal Seminoma Occurring After Intracranial Germinoma in an Adolescent
33. Prenatal Diagnosis and Subsequent Treatment of an Intermediate-Risk Paraspinal Neuroblastoma: Case Report and Review of the Literature
34. Emergence and Compartmentalization of Fatal Multi-Drug-Resistant Cytomegalovirus Infection in a Patient With Autosomal-Recessive Severe Combined Immune Deficiency
35. Identification and functional characterization of thromboxane A2receptors in Schwann cells
36. Postcesarean Analgesia with Both Epidural Morphine and Intravenous Patient-Controlled Analgesia
37. The Identification and Characterization of Oligodendrocyte Thromboxane A2 Receptors
38. Postcesarean Analgesia with Both Epidural Morphine and Intravenous Patient-Controlled Analgesia
39. Toxicology screening in adolescent trauma
40. Assessment of Cellular Localization of the Thromboxane A2 Receptor by Immunocytochemistry.
41. Opioid Antagonist Adjuncts to Epidural Morphine for Postcesarean Analgesia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.